Charted
Wednesday, Nov. 18, 2026The business of health, by the numbers
Live trackersDeal tracker $7.07B raisedFDA clearances 293 510(k)s in OctoberForm D raises $839M in 30 daysNew trials 266 Phase 2/3 in 30 days
Devices & FDA·Medtronic

Medtronic's Hugo robot gets FDA clearance for general surgery, from gallbladders to hernias

Medtronic said an expanded 510(k) clears its Hugo robot for upper abdominal general surgery, inguinal hernia and appendectomy, less than a year after its first U.S. clearance for urology. No gynecology decision has been announced.

Charted Staff2 min read
From Medtronic announcements published Nov. 17 and June 3, 2026, coverage by MedTech Dive published Nov. 17, and FDA's 510(k) database and openFDA records for the system's 2025 clearance
Components of Medtronic's Hugo robotic-assisted surgery system, including the open surgeon console, the system tower and a robotic arm cart.
Components of Medtronic's Hugo robotic-assisted surgery system, including the open surgeon console, the system tower and a robotic arm cart.Courtesy of Medtronic

Medtronic said its Hugo surgical robot can now be marketed in the U.S. for general surgery. In a Nov. 17 announcement, the company said the Food and Drug Administration had cleared the system, through an expanded 510(k), for all upper abdominal general surgical procedures, including gallbladder removal, Roux-en-Y gastric bypass, ventral hernia repair and small bowel resection, plus two lower abdominal operations, inguinal hernia repair and appendectomy.

Medtronic said those procedures add up to about 3.5 million U.S. surgeries a year, more than half of all soft-tissue procedures performed in the country. Until now, Hugo's U.S. label covered only urologic surgery.

Why it matters: The clearance moves Hugo beyond urology into a specialty Medtronic called one of the fastest-growing areas of U.S. robotic surgery, and one where, the company said, its open and laparoscopic technologies have been used for more than half a century. It can now offer Hugo to general surgery programs, not only urology programs. MedTech Dive noted that Hugo's first U.S. clearance, for urology in December 2025, made Medtronic the first large medtech company to bring a soft-tissue robotic platform to the U.S. market since Intuitive launched its da Vinci system in 2000.

The regulatory path

FDA first cleared the Hugo RAS System on Dec. 3, 2025, under K250725, for minimally invasive urologic procedures in adults, according to FDA's 510(k) database. That submission, filed under the name Covidien LLC of North Haven, Conn., took nearly nine months from receipt to decision and was reviewed by the general and plastic surgery panel under product code SCV.

On June 3, Medtronic said it had submitted 510(k)s for a general surgery indication, including hernia repair, and for gynecologic surgery, and had finished enrolling 70 patients at five U.S. hospitals in its Embrace Gynecology study. The Nov. 17 announcement covered only general surgery. Medtronic did not give the new clearance's 510(k) number or decision date, and the clearance did not yet appear in FDA's 510(k) data as published through openFDA, last updated Nov. 9.

"For decades, Medtronic has partnered with general surgeons, and we're bringing that same commitment to robotic surgery for U.S. customers," Matt Anderson, senior vice president and president of Medtronic's surgical business, said in the announcement.

A crowding field

Hugo is one of several soft-tissue robots gaining U.S. indications. Johnson & Johnson received FDA authorization in July for its Ottava system in general surgery, according to MedTech Dive. FDA cleared CMR Surgical's Versius Plus, which shares the SCV product code and has been cleared for gallbladder removal since December 2025, for six gynecologic procedures on Oct. 21, with Stryker set to handle its U.S. sales. On Oct. 30 the agency granted a De Novo to Virtuoso Surgical for a robotic endoscopy system used in bladder procedures.

Medtronic said surgeons can use its LigaSure RAS Maryland vessel-sealing instrument on Hugo. The company said Hugo procedures worldwide are growing more than twice as fast as the robotic surgery market and are on track to pass 50,000 by the end of its fiscal year, and that general surgery is the fastest-growing Hugo specialty outside the U.S.

What comes next

The open questions are the gynecology submission and how quickly U.S. hospitals add Hugo for general surgery. Medtronic said the system is in clinical use at a growing number of U.S. health systems and hospitals but did not give a count or a timeline for the gynecology decision.

Stories bylined Charted Staff are produced by the Charted newsroom from public documents: company announcements, SEC filings, FDA databases and federal rules. Each one lists the documents it was drawn from. Drafted with automated tools from the sources listed with this story and checked against them before publishing. How we report.

More Devices & FDA

More
Newsletter

Charted Daily

The day's deals, FDA decisions and policy moves, by the numbers. Free. Sign up now to get the first edition.

No spam. Unsubscribe any time.